SensPD News
4 articles
growth-positive
Worldwide Business with kathy ireland®: See SensPD Introduce Their Revolutionary Method to Detect Autism at Birth
SensPD, a company based in Tel Aviv, Israel, is developing a technology to detect autism shortly after birth. Their mission is to ensure that all newborn babies are properly tested for autism so that early interventions can be provided. SensPD uses a physiological marker to objectively detect autism, rather than relying on behavioral observations. The screening test is simple and non-invasive, utilizing the sense of hearing to measure sensory perception. The results are then sent to the cloud for analysis. SensPD aims to be the main screening test for autism right after birth, with the goal of improving the lives of affected children from the start. The article features an exclusive interview with SensPDs Founder and Research Leader, Raffi Rembrand, and CEO and Co-Founder, Maayan Shahar.
Customers
growth-positive
3 Recent Israeli-Led Breakthrough Discoveries In Autism Research
Israeli researchers and companies are making groundbreaking developments in autism research. One Israeli company, SensPD, has developed a non-invasive diagnostic test that can screen newborns and infants for signs of autism. Another development is the use of medical cannabis, specifically cannabidiol (CBD), as an alternative treatment for autism. A study conducted in Israel showed significant improvements in symptoms such as self-injury, hyperactivity, and sleep problems after using CBD. Additionally, a study led by an Israeli professor found that women who take folic acid supplements and multivitamins before and during pregnancy have a reduced risk of having a child with autism.
Customers
growth-positive
SensPD Enters its First Round of Funding to Launch its Breakthrough Software Technology for the Early Detection of Autism in Newborns
SensPD, an Israeli start-up, aims to revolutionize the digital health market with its method for early objective detection of autism in newborns. The company uses Oto Acoustic Emission (OAE) devices to diagnose the brainstems response through vocal stimuli. SensPD is currently in clinical trials and plans to launch its product on a market-wide scale by the end of 2019. The company is seeking investors to support its go-to-market launch set for late 2018. SensPD has a solid advisory board and management team, and its market is estimated to be over $1 billion.
InvestmentExpand
growth-positive
Israeli dad shows how newborns can be screened for autism
SensPD, a startup founded by Raphael Rembrand, is developing a noninvasive diagnostic process to screen newborns for signs of autism. The process uses the same instrument currently used to test infants hearing and measures otoacoustic emissions as an indicator of the babys overall sensory perception. SensPD aims to detect autism earlier, allowing for early intervention and better outcomes. The company is ready for clinical trials and has enlisted hospitals in the US and Israel for the studies. SensPDs business model is to charge for the database analysis rather than the screening test. The founder has self-funded the company and won a $100,000 prize in a competition. SensPD is seeking funding to support its clinical studies.
Customers
